Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Aaron R. Mangold
- Study ID
- NCT04492618
- Phase
- PHASE2
- Status
- Completed
Conditions
- Necrobiosis Lipoidica
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ruxolitinib — DRUGRuxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica
Study Details
This research study is evaluating the safety and efficacy of a topical drug treatment "Ruxolitinib" in treating Necrobiosis Lipoidica (NL).
Key Dates
- Start date
- Sep 29, 2020
- Status verified
- Jan 2023
- Primary completion
- Mar 16, 2022
- Completion
- Mar 16, 2022
Study Design
- Enrollment
- 12 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Necrobiosis LipoidicaAdults with cutaneous Necrobiosis Lipoidica (NL) up to 10% of the body surface area (BSA) treated with Ruxolitinib cream
Primary Outcome Measure
Change in Mean Necrobiosis Lipoidica (NL) Lesion Score [ Time Frame: Baseline, week 12 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | - |
Find similar trials in Scottsdale, AZ
By research site